ANI Pharmaceuticals Inc. (ANIP) Trading 5.2% Higher
ANI Pharmaceuticals Inc. (NASDAQ:ANIP) shares traded up 5.2% on Tuesday . The company traded as high as $70.79 and last traded at $70.49, with a volume of 144,433 shares changing hands. The stock had previously closed at $67.00.
A number of research analysts recently weighed in on the stock. Guggenheim reissued a “buy” rating and set a $80.00 price target (up from $65.00) on shares of ANI Pharmaceuticals in a research report on Friday, August 5th. Oppenheimer Holdings Inc. raised their price target on shares of ANI Pharmaceuticals from $65.00 to $71.00 and gave the company an “outperform” rating in a research report on Friday, August 5th. Zacks Investment Research raised shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $67.00 price target on the stock in a research report on Wednesday, July 20th. Citigroup Inc. raised shares of ANI Pharmaceuticals to an “outperform” rating and set a $65.00 price target on the stock in a research report on Tuesday, July 19th. Finally, Raymond James Financial Inc. assumed coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, June 22nd. They set a “strong-buy” rating and a $68.00 price target on the stock. Two investment analysts have rated the stock with a hold rating, four have given a buy rating and three have given a strong buy rating to the company’s stock. ANI Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $64.00.
The company has a market cap of $791.36 million and a price-to-earnings ratio of 80.76. The company has a 50 day moving average of $58.77 and a 200 day moving average of $45.44.
ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Thursday, August 4th. The specialty pharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.77 by $0.34. The company had revenue of $31.30 million for the quarter, compared to analysts’ expectations of $27.63 million. During the same period in the previous year, the firm posted $0.55 earnings per share. The firm’s revenue for the quarter was up 60.5% compared to the same quarter last year. On average, equities research analysts forecast that ANI Pharmaceuticals Inc. will post $4.12 EPS for the current year.
In other ANI Pharmaceuticals news, VP Robert W. Schrepfer sold 12,500 shares of the business’s stock in a transaction on Monday, August 8th. The shares were sold at an average price of $67.06, for a total transaction of $838,250.00. Following the transaction, the vice president now directly owns 17,362 shares of the company’s stock, valued at approximately $1,164,295.72. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
A hedge fund recently raised its stake in ANI Pharmaceuticals stock. Mutual of America Capital Management LLC increased its position in shares of ANI Pharmaceuticals Inc. (NASDAQ:ANIP) by 0.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 30,178 shares of the specialty pharmaceutical company’s stock after buying an additional 178 shares during the period. Mutual of America Capital Management LLC owned about 0.26% of ANI Pharmaceuticals worth $1,362,000 as of its most recent filing with the SEC.
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company’s focused areas of product development include anti-cancer (oncolytics), hormones and steroids, and complex formulations.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.